The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk
Open accessAbstract
Importance: Some cholesteryl ester transfer protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels without reducing cardiovascular events, suggesting that the clinical benefit of lowering LDL-C may depend on how LDL-C is lowered. Objective: To estimate the association between changes in levels of LDL-C (and other lipoproteins) and the risk of cardiovascular events related to variants in the CETP gene, both alone and in combination with variants in the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene. Design, Setting, and Participants: Mendelian randomization analyses evaluating the association between CETP and HMGCR scores, changes in lipid and lipoprotein levels, and the risk of cardiovascular events involving 102 837 participants from 14 cohort or case-control studies conducted in North America or the United Kingdom between 1948 and 2012. The associations with cardiovascular events were externally validated in 189 539 participants from 48 studies conducted between 2011 and 2015. Exposures: Differences in mean high-density lipoprotein cholesterol (HDL-C), LDL-C, and apolipoprotein B (apoB) levels in participants with CETP scores at or above vs below the median. Main Outcomes and Measures: Odds ratio (OR) for major cardiovascular events. Results: The primary analysis included 102 837 participants (mean age, 59.9 years; 58% women) who experienced 13 821 major cardiovascular events. The validation analyses included 189 539 participants (mean age, 58.5 years; 39% women) with 62 240 cases of coronary heart disease (CHD). Considered alone, the CETP score was associated with higher levels of HDL-C, lower LDL-C, concordantly lower apoB, and a corresponding lower risk of major vascular events (OR, 0.946 [95% CI, 0.921-0.972]) that was similar in magnitude to the association between the HMGCR score and risk of major cardiovascular events per unit change in levels of LDL-C (and apoB). When combined with the HMGCR score, the CETP score was associated with the same reduction in LDL-C levels but an attenuated reduction in apoB levels and a corresponding attenuated nonsignificant risk of major cardiovascular events (OR, 0.985 [95% CI, 0.955-1.015]). In external validation analyses, a genetic score consisting of variants with naturally occurring discordance between levels of LDL-C and apoB was associated with a similar risk of CHD per unit change in apoB level (OR, 0.782 [95% CI, 0.720-0.845] vs 0.793 [95% CI, 0.774-0.812]; P = .79 for difference), but a significantly attenuated risk of CHD per unit change in LDL-C level (OR, 0.916 [95% CI, 0.890-0.943] vs 0.831 [95% CI, 0.816-0.847]; P < .001) compared with a genetic score associated with concordant changes in levels of LDL-C and apoB. Conclusions and Relevance: Combined exposure to variants in the genes that encode the targets of CETP inhibitors and statins was associated with discordant reductions in LDL-C and apoB levels and a corresponding risk of cardiovascular events that was proportional to the attenuated reduction in apoB but significantly less than expected per unit change in LDL-C. The clinical benefit of lowering LDL-C levels may therefore depend on the corresponding reduction in apoB-containing lipoprotein particles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, Mendelian randomization studies demonstrated that the reduction in cardiovascular risk associated with genetic variation in clearance and processing of apoB-containing lipoproteins, including LDL particles as well as TG-rich VLDL particles and their remnants, was correlated with the change of concentration of these particles as measured by apoB rather than the cholesterol mass carried”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [79]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the results of this study are consistent with a recent mendelian randomization study that demonstrated that the causal effect of LDL particles on the risk of cardiovascular disease appears to be determined by the concentration of circulating LDL particles as measured by ApoB rather than by the mass of cholesterol carried by those particles as measured by LDL-C.23”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [23]
In the citing paper
“Fibrates are associated with a slightly increased risk of pancreatitis [321].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [321]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677
Self-citationFerence, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationBiological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationWiller (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Self-citationA comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationLarge-scale association analysis identifies new risk loci for coronary artery disease
The CARDIoGRAMplusC4D Consortium, Deloukas, P., DIAGRAM Consortium, CARDIOGENICS Consortium, MuTHER Consortium, Wellcome Trust Case Control Consortium, Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2480 · Cited by 1,614
Flagged first, then by citations
Research works printed but not linked: 4
- [10]10. Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP). Lancet. 2015;386(9992):452-460.
- [19]19. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in mendelian randomization. Stat Med. 2016;35(11):1880-1906.
- [20]20. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments. Int J Epidemiol. 2015;44(2):512-525.
- [22]22. Moore C, Sambrook J, Walker M, et al. The INTERVAL trial to determine whether intervals between blood donations can be safely and acceptably decreased to optimise blood supply. Trials. 2014;15:363.
Cited by
Sorted by citations
Items 101–200 of 304
Lowering low-density lipoprotein cholesterol: from mechanisms to therapies
Luo, J., Wang, J.-K., & Song, B. (2022) · Life Metabolism · doi:10.1093/lifemeta/loac004 · Cited by 37
From lipid locus to drug target through human genomics
van der Laan, S. W., Harshfield, E. L., Hemerich, D., Stacey, D., Wood, A., & Asselbergs, F. W. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy120 · Cited by 33
Larsen, L. E., Stoekenbroek, R. M., Kastelein, J. J. P., & Holleboom, A. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312028 · Cited by 34
Self-citationSniderman, A. D., Pencina, M. J., & Thanassoulis, G. (2019) · Circulation Research · doi:10.1161/circresaha.119.315019 · Cited by 34
Association of genetically predicted lipid traits and lipid-modifying targets with heart failure
Xiao, J., Ji, J., Zhang, N., Yang, X., Chen, K., Chen, L., & Huang, W. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac290 · Cited by 30
Multitrait GWAS to connect disease variants and biological mechanisms
Julienne, H., Laville, V., McCaw, Z. R., He, Z., Guillemot, V., Lasry, C., Ziyatdinov, A., Nerin, C., Vaysse, A., Lechat, P., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009713 · Cited by 35
Zein, M. A., Khazzeka, A., Khoury, A. E., Zein, J. A., Dima, Z., & Eid, A. H. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.10.009 · Cited by 35
Gonna, H., & Ray, K. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13691 · Cited by 30
Self-citationJoshi, R., Wannamethee, S. G., Engmann, J., Gaunt, T. R., Lawlor, D. A., Price, J. F., Papacosta, O., Shah, T., Tillin, T., Chaturvedi, N., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319899621 · Cited by 30
Causal Effect of Lipids and Lipoproteins on Atherosclerosis
Ference, B. A. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.001 · Cited by 28
Self-citationBacquer, D. D., Smedt, D. D., Reiner, Ž., Tokgözoğlu, L. S., Clays, E., Kotseva, K., Rydén, L., Wood, D., & Backer, G. D. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319874898 · Cited by 29
Gormley, M., Yarmolinsky, J., Dudding, T., Burrows, K., Martin, R. M., Thomas, S. J., Tyrrell, J., Brennan, P., Pring, M., Boccia, S., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009525 · Cited by 32
Self-citationHuman Genetics and Drug Development
Holmes, M. V. (2019) · New England Journal of Medicine · doi:10.1056/nejme1901565 · Cited by 28
Li, M., Zhao, J. V., Kwok, M. K., & Schooling, C. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-88256-x · Cited by 26
HDL and Reverse Cholesterol Transport Biomarkers
Riggs, K. A., & Rohatgi, A. K. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-39 · Cited by 26
CETP‐Inhibition and HDL‐Cholesterol: A Story of CV Risk or CV Benefit, or Both
Nicholls, S. J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1118 · Cited by 25
Self-citationReprint of: Impact of Lipids on Cardiovascular Health
Ference, B. A., Graham, I. M., Tokgözoğlu, L. S., & Catapano, A. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.021 · Cited by 26
Self-citationResidual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
Kim, C.-W., Hong, S., Chang, Y., Lee, J. A., Shin, H., & Ryu, S. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-0692 · Cited by 25
Host genetics and gut microbiota jointly regulate blood biochemical indicators in chickens
Jiang, X., Zhang, B., Lan, F., Zhong, C., Jin, J., Li, X., Zhou, Q., Li, J., Yang, N., Wen, C., et al. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12814-8 · Cited by 26
Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives
Karantas, I. D., Okur, M. E., Okur, N. Ü., & Siafaka, P. I. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200810144004 · Cited by 25
New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
Pirillo, A., & Catapano, A. L. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000706 · Cited by 25
Self-citationApplying Mendelian randomization to appraise causality in relationships between nutrition and cancer
Wade, K. H., Yarmolinsky, J., Giovannucci, E. L., Lewis, S. J., Millwood, I. Y., Munafo, M. R., Meddens, S. F. W., Burrows, K., Bell, J. A., Davies, N. M., et al. (2022) · Cancer Causes & Control · doi:10.1007/s10552-022-01562-1 · Cited by 25
Self-citationRehman, W. U., Yarkoni, M., Ilyas, M. A., Athar, F., Javaid, M., Ehsan, M. T., Khalid, M. T., Pasha, A. K., Selma, A. B., Yarkoni, A., et al. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050152 · Cited by 26
Arnold, N., Blaum, C. M., Goßling, A., Brunner, F. J., Bay, B., Zeller, T., Ferrario, M. M., Brambilla, P., Cesana, G., Leoni, V., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.050 · Cited by 24
Hartgers, M. L., Besseling, J., Stroes, E. S. G., Wittekoek, J., Rutten, J. H. W., Graaf, J. D., Visseren, F. L. J., Imholz, B. P. M., van Lennep, J. E. R., Huijgen, R., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.04.002 · Cited by 24
Self-citationSobczyk, M., Zheng, J., Smith, G. D., & Gaunt, T. R. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072087 · Cited by 26
Self-citationSun, J., Zhang, H., Zhang, Y., Wang, L., Sun, B., Gao, F., & Liu, G. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.03.012 · Cited by 24
Schmitz, T., Freuer, D., Linseisen, J., & Meisinger, C. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100399 · Cited by 22
Penson, P. E., & Banach, M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00887-z · Cited by 23
Liu, Z., Ye, T., Sun, B., Schooling, M., & Tchetgen, E. T. (2022) · Biometrics · doi:10.1111/biom.13735 · Cited by 25
Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
Filippatos, T. D., Kei, A. A., & Elisaf, M. (2017) · Diseases · doi:10.3390/diseases5040021 · Cited by 22
Apolipoprotein B: the Rosetta Stone of lipidology
Glavinovic, T., & Sniderman, A. D. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000596 · Cited by 22
Sweeney, T. E., Quispe, R., Das, T. M., Juraschek, S. P., Martin, S. S., & Michos, E. D. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1930531 · Cited by 24
Beyond LDL-C levels, does remnant cholesterol estimation matter?
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319899622 · Cited by 22
Self-citationAli, L., Cupido, A. J., Rijkers, M., Hovingh, G. K., Holleboom, A. G., Dallinga‐Thie, G. M., Stroes, E. S. G., & van den Boogert, M. A. W. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.07.001 · Cited by 21
The mystery of evacetrapib - why are CETP inhibitors failing?
Nicholls, S. J., & Bubb, K. J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1745633 · Cited by 21
Self-citationApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk
Sehayek, D., Cole, J., Björnson, E., Wilkins, J. T., Mortensen, M. B., Dufresne, L., Pencina, K. M., Pencina, M. J., Thanassoulis, G., & Sniderman, A. D. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.05.024 · Cited by 20
LDL cholesterol: How low to go?
Packard, C. J. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.12.011 · Cited by 20
Self-citationNew Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease
Katzmann, J. L., & Laufs, U. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1159-z · Cited by 19
Self-citationCan we revive CETP-inhibitors for the prevention of cardiovascular disease?
Nicholls, S. J., Ray, K. K., Nelson, A. J., & Kastelein, J. J. P. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000854 · Cited by 19
Self-citationCETP Inhibitors: Should We Continue to Pursue This Pathway?
Nicholls, S. J., & Nelson, A. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01070-2 · Cited by 19
Self-citationJin, D., Trichia, E., Islam, N., Bešević, J., Lewington, S., & Lacey, B. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029552 · Cited by 19
Yu, C., Bakshi, A., Watts, G. F., Renton, A. E., Fulton‐Howard, B., Goate, A., Natarajan, P., Chasman, D. I., Robman, L. D., Woods, R. L., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031459 · Cited by 20
Self-citationTrompet, S., Packard, C. J., & Jukema, J. W. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000476 · Cited by 19
Self-citationJohannesen, C. D. L., Mortensen, M. B., Nordestgaard, B. G., & Langsted, A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119139 · Cited by 22
Trinder, M., & Brunham, L. R. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000737 · Cited by 17
Ibrahim, M. A., Thanigaimani, S., Singh, T. P., Morris, D., & Golledge, J. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100836 · Cited by 17
A Comparison of Lipids and apoB in Asian Indians and Americans
Singh, K., Thanassoulis, G., Dufresne, L., Nguyen, A., Gupta, R., Narayan, K. M. V., Tandon, N., Sniderman, A. D., & Prabhakaran, D. (2021) · Global Heart · doi:10.5334/gh.882 · Cited by 16
Holmes, M. V., & Smith, G. D. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.10.006 · Cited by 16
Self-citationYao, T., Lu, W., Ke, J., Zhang, H., Zhao, X., Song, B., Liu, T., Ke, Q., & Liu, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.865863 · Cited by 16
Yu, Z., Hu, L., Sun, C., Wang, Z., Zhang, X., Wu, M., & Liu, L. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001419 · Cited by 14
O’Keeffe, L. M., Bell, J. A., O’Neill, K. N., Lee, M., Woodward, M., Peters, S. A. E., Smith, G. D., & Kearney, P. M. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003636 · Cited by 15
Self-citationDavidson, M. H., Hsieh, A., & Kastelein, J. J. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000955 · Cited by 15
Self-citationProteomic studies on apoB-containing lipoprotein in cardiovascular research: A comprehensive review.
Gianazza, E., Zoanni, B., Mallia, A., Brioschi, M., Colombo, G., & Banfi, C. (2021) · Mass spectrometry reviews (Print) · doi:10.1002/mas.21747 · Cited by 10
Wu, Y., Xu, W., Guo, L., Li, W., Zhang, L., Gao, L., Zhu, C., Chen, S., Lin, L., & Wu, S. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01852-w · Cited by 14
Cholesteryl ester transfer protein inhibitors in precision medicine
Su, X., Li, G., Deng, Y., & Chang, D. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.09.012 · Cited by 14
PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study
Lyall, D. M., Ward, J., Banach, M., Smith, G. D., Gill, J. M. R., Pell, J. P., Holmes, M. V., & Sattar, N. A. (2021) · Archives of Medical Science · doi:10.5114/aoms/127226 · Cited by 15
Self-citationReduced CETP glycosylation and activity in patients with homozygous B4GALT1 mutations
van den Boogert, M. A. W., Crunelle, C. L., Ali, L., Larsen, L. E., Kuil, S. D., Levels, J. H. M., Schimmel, A. W. M., Konstantopoulou, V., Guérin, M., Kuivenhoven, J. A., et al. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12200 · Cited by 13
Packard, C. J. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1003-x · Cited by 13
Self-citationLanglois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H. H. E., Borén, J., Bruckert, É., Catapano, A. L., Cobbaert, C. M., et al. (2021) · Laboratory Service · doi:10.17116/labs20211001145 · Cited by 13
Self-citationTranslational Genomics in Neurocritical Care: a Review
Myserlis, E. P., Radmanesh, F., & Anderson, C. D. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00838-1 · Cited by 12
Christen, T., Trompet, S., Noordam, R., Blauw, L. L., Gast, K. B., Rensen, P. C. N., van Dijk, K. W., Rosendaal, F. R., de Mutsert, R., & Jukema, J. W. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.023 · Cited by 12
Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk
Barter, P. J., & Rye, K. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.011 · Cited by 12
Liu, L., Sheng, C., Lyu, Z., Dai, H., & Chen, K. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.755834 · Cited by 12
Sniderman, A. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.010 · Cited by 12
Bempedoic acid and ezetimibe – better together
Khan, S. U., & Michos, E. D. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319864672 · Cited by 12
Nicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Návar, A. M., Nissen, S. E., Goldberg, A. C., Brunham, L. R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04179-4 · Cited by 12
Self-citationAchieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 12
Self-citationLi, W., Liu, X., Huang, C., Liu, L., Tan, X., & Wang, X. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.10.019 · Cited by 12
Srisawasdi, P., Rodcharoen, P., Vanavanan, S., Chittamma, A., Sukasem, C., Nakorn, C. N., Dejthevaporn, C., & Kroll, M. H. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s278671 · Cited by 13
Wu, J., Wang, Y., Kang, K., Wang, A., Xu, J., & Zhao, X. (2021) · Stroke and Vascular Neurology · doi:10.1136/svn-2020-000430 · Cited by 11
Effect of NPC1L1 and HMGCR Genetic Variants With Premature Triple-Vessel Coronary Disease
Zhao, X., Xu, J., Tang, X., Huang, K., Li, J., Liu, R., Jiang, L., Zhang, Y., Wang, D., Sun, K., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.704501 · Cited by 11
Fujino, M., Giovanni, G. D., Butters, J., Kataoka, Y., Hucko, T., Nelson, A. J., Nissen, S. E., Psaltis, P. J., & Nicholls, S. J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119145 · Cited by 10
Self-citationLipids and Lipoproteins in Risk Prediction
Hadjiphilippou, S., & Ray, K. K. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.002 · Cited by 10
Self-citationGeorgiou, A. N., Zagkos, L., Markozannes, G., Chalitsios, C. V., Asimakopoulos, A., Xu, W., Wang, L., Mesa‐Eguiagaray, I., Zhou, X., Loizidou, E. M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029040 · Cited by 10
Li, M., Kwok, M.-K., & Schooling, C. M. (2021) · Nutrients · doi:10.3390/nu13072215 · Cited by 10
The association of apolipoprotein B with chronic kidney disease in the Chinese population
Xu, Y., Liu, B., Lin, L.-J., Lei, F., Sun, T., Zhang, X.-Y., Song, X.-H., Huang, X.-W., Zeng, Q., Cai, J.-J., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1083614 · Cited by 9
Nordestgaard, L. T., Hanson, A., Sanderson, E. C. M., Anderson, E. L., Walker, V. M., Tybjærg‐Hansen, A., Smith, G. D., & Nordestgaard, B. G. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70638 · Cited by 12
Self-citationHigh Density Lipoproteins: Is There a Comeback as a Therapeutic Target?
von Eckardstein, A. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_536 · Cited by 9
Tokgözoğlu, L. S., Pirillo, A., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad485 · Cited by 9
Self-citationFerence, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
Self-citationYang, R., Wu, S., Zhao, Z., Deng, X., Deng, Q.-Y., Wang, D., & Liu, Q. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02420-7 · Cited by 8
Educational Attainment and Ischemic Stroke: A Mendelian Randomization Study
Gao, L., Wang, K., Ni, Q., Fan, H., Zhao, L., Huang, L., Yang, M., & Li, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.794820 · Cited by 8
Li, Z., Tian, M., Jia, H., Li, X., Liu, Q., Zhou, X., Li, R., Dong, H., & Liu, Y. (2023) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2023.2255622 · Cited by 8
Genetic contribution to lipid target achievement with statin therapy: a prospective study
Ruiz-Iruela, C., Candás‐Estébanez, B., Pintó, X., Baena, N., Caixàs, A., Güell-Miró, R., Navarro-Badal, R., Calmarza, P., Puzo, J., Alía‐Ramos, P., et al. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0136-7 · Cited by 8
Zhao, X., Li, J., Tang, X., Liu, R., Xu, J., Xu, L., Jiang, L., Huang, K., Tian, J., Feng, X., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.229 · Cited by 9
Anacetrapib as a potential cardioprotective strategy
Bartolo, B. A. D., & Nicholls, S. J. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s114104 · Cited by 8
Self-citationSun, C., Brisson, D., Gaudet, D., & Ooi, T. C. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.09.006 · Cited by 9
Pirillo, A., & Catapano, A. L. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318820976 · Cited by 8
Self-citationChoi, R., Lee, S. G., & Lee, E. H. (2024) · Metabolites · doi:10.3390/metabo14030169 · Cited by 7
Young, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Lower LDL is better – can this be achieved with CETP inhibition therapy?
Rashid, S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1715797 · Cited by 7
Chen, K., Pan, Y., Wang, Y., Luan, M., Yan, H., Yu, J., Xin, D., Zhao, Y., Xu, X., Li, M., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07269-6 · Cited by 6
Emara, A., Gadelmawla, A. F., Awashra, A., Rifai, M. K., Elgendy, M. S., Diaa, A., Emara, M. R., Odat, R. M., Assaassa, A., & Shubietah, A. R. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70316 · Cited by 6
Kolanu, N. D., Syeda, Z. R., Joshi, N., Singh, P., & Erukulla, M. (2024) · Cureus · doi:10.7759/cureus.57742 · Cited by 7
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?
Nicholls, S. J., Tan, S., Butters, J., & Nelson, A. J. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2409324 · Cited by 6
Self-citationA translational framework of genoproteomic studies for cardiovascular drug discovery
Yang, Z., Zhao, J. V., Qi, Y., Deng, X., Ji, Z., & Liu, J. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00015-9 · Cited by 6
Genetic Studies Help Clarify the Complexities of Lipid Biology and Treatment
Sniderman, A. D., & Peterson, E. D. (2017) · JAMA · doi:10.1001/jama.2017.11750 · Cited by 6
Laufs, U., & Speer, T. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab889 · Cited by 6
Self-citation
Metadata
- Authors
- Ference, B. A., Kastelein, J. J. P., Ginsberg, H. N., Chapman, M. J., Nicholls, S. J., Ray, K. K., Packard, C. J., Laufs, U., Brook, R. D., Oliver-Williams, C., Butterworth, A. S., Danesh, J., Smith, G. D., Catapano, A. L., & Sabatine, M. S.
- Affiliations
- Wayne State University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Columbia University Irving Medical Center (US)
- Inserm (FR)
- South Australian Health and Medical Research Institute (AU)
- Imperial College London (GB)
- University of Glasgow (GB)
- Leipzig University (DE)
- University of Michigan (US)
- MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
- University of Cambridge (GB)
- University of Bristol (GB)
- University of Milan (IT)
- Brigham and Women's Hospital (US)
- Corresponding author
- Ference, Brian A.
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-09-12
- Volume
- 318
- Issue
- 10
- Pages
- 947
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5710502
- OpenAlex
- W2749237115
- Cited by
- 304
- References
- 34
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 23 · 2023: 34 · 2022: 28 · 2021: 41 · 2020: 43 · 2019: 46 · 2018: 37 · 2017: 15
- FWCI
- 39.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Apollo (University of Cambridge) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Apollo
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Biogen
- NHS Blood and Transplant
- Regeneron Pharmaceuticals
- Wellcome Trust
- National Institute for Health and Care Research (NF-SI-0512-10165, MC_UU_12013/1)
- British Heart Foundation (CH/12/2/29428, RG/13/13/30194, RG/16/4/32218, RG/08/014/24067)
- Bupa Foundation
- European Commission (279143, 279233)
- University of Bristol (MC_UU_12013/1)
- Cambridge University Hospitals (3819-1516-29, BRC 2012-2017, 3819-1617-25, 146281)
- Evelyn Trust
- Medical Research Council (MC_UU_12013, MR/L003120/1, MR/M012816/1, MCUU12013/1, MR/P013880/1)
- Homerton College, University of Cambridge
- National Heart, Lung, and Blood Institute
- Fogarty International Center
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- cholesteryl ester transfer protein, statins, CETP inhibitors, LDL cholesterol, HDL cholesterol, apolipoprotein B, lipoprotein levels, cardiovascular risk, coronary artery disease, major adverse cardiovascular events, lipid-lowering therapy, Mendelian randomization
- MeSH terms
- Anticholesteremic Agents, Apolipoproteins B, Cardiovascular Diseases, Female, Humans, Hydroxymethylglutaryl CoA Reductases, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Genetic Variation, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cholesterol Ester Transfer Proteins, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
